好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Natalizumab Reduces Total Disability Burden Relative to Placebo in Patients with Relapsing-Remitting Multiple Sclerosis Regardless of the Occurrence of Relapses or Confirmed Disability Progression or Improvement over 2 Years in the AFFIRM Study
Multiple Sclerosis
(-)
244
Authors/Disclosures

PRESENTER 		No disclosure on file
No disclosure on file
Qunming Dong No disclosure on file
Richard A. Rudick, MD, FAAN (Optimal Brain Health Consultants) Dr. Rudick has received personal compensation for serving as an employee of Biogen. Dr. Rudick has received stock or an ownership interest from Biogen. Dr. Rudick has received publishing royalties from a publication relating to health care.
Daniel D. Mikol, MD, PhD (Abbvie) Dr. Mikol has received personal compensation for serving as an employee of NervGen. Dr. Mikol has received personal compensation for serving as an employee of Amgen. Dr. Mikol has received personal compensation in the range of $100,000-$499,999 for serving as an officer or member of the Board of Directors for NervGen. Dr. Mikol has stock in NervGen. Dr. Mikol has stock in Amgen. Dr. Mikol has received personal compensation in the range of $100,000-$499,999 for serving as a Employee with NervGen.
No disclosure on file